Viveve Medical Inc (NASDAQ:VIVE) Expected to Announce Quarterly Sales of $3.92 Million
Wall Street analysts expect Viveve Medical Inc (NASDAQ:VIVE) to announce $3.92 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Viveve Medical’s earnings, with the highest sales estimate coming in at $4.50 million and the lowest estimate coming in at $3.33 million. Viveve Medical posted sales of $5.53 million during the same quarter last year, which suggests a negative year-over-year growth rate of 29.1%. The business is expected to issue its next earnings results after the market closes on Thursday, August 8th.
On average, analysts expect that Viveve Medical will report full year sales of $12.44 million for the current year, with estimates ranging from $9.48 million to $15.40 million. For the next fiscal year, analysts anticipate that the firm will report sales of $19.32 million, with estimates ranging from $18.23 million to $20.40 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Viveve Medical.
VIVE has been the subject of a number of research reports. Mizuho cut shares of Viveve Medical from a “buy” rating to an “underperform” rating and cut their price target for the stock from $4.00 to $0.20 in a research note on Tuesday, July 23rd. Stifel Nicolaus cut shares of Viveve Medical from a “buy” rating to a “hold” rating and cut their price target for the stock from $3.00 to $1.00 in a research note on Monday, July 22nd. Maxim Group reissued a “hold” rating on shares of Viveve Medical in a research note on Friday, August 9th. LADENBURG THALM/SH SH cut shares of Viveve Medical from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 24th. Finally, Raymond James lowered shares of Viveve Medical from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Viveve Medical has a consensus rating of “Hold” and an average target price of $2.24.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Meitav Dash Investments Ltd. boosted its holdings in Viveve Medical by 30.1% during the first quarter. Meitav Dash Investments Ltd. now owns 988,573 shares of the company’s stock worth $955,000 after purchasing an additional 228,517 shares during the last quarter. Pennsylvania Trust Co raised its position in Viveve Medical by 212.3% in the first quarter. Pennsylvania Trust Co now owns 42,154 shares of the company’s stock worth $7,681,000 after acquiring an additional 28,654 shares during the period. Accredited Investors Inc. bought a new stake in Viveve Medical in the first quarter worth about $31,000. Geode Capital Management LLC raised its position in Viveve Medical by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock worth $227,000 after acquiring an additional 25,975 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Viveve Medical by 266.6% in the fourth quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock worth $47,000 after acquiring an additional 32,888 shares during the period. 59.64% of the stock is owned by institutional investors.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
See Also: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.